Patent intelligence · US
US 11672785
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
Patent details — US 11672785
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 13, 2023
- Expiration
- Jun 8, 2043
- Applicant
- Olema Pharmaceuticals, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/4545, A61K31/475
Quick answer
US 11672785 (Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Olema Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/437, A61K31/4545, A61K31/475, A61K31/506, A61K45/06
More from Olema Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428379
Acylsulfonamide KAT6A inhibitors
granted -
US 12370181
Regimens of estrogen receptor antagonists
granted -
US 11229630
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10624878
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10292971
Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
granted -
US 9018244
Benzopyran compounds, compositions and uses thereof
granted -
US 8071545
Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
granted
Frequently asked questions
What is US patent 11672785?
US 11672785 (Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11672785?
Olema Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11672785 expire?
Our index shows an expiration date of Jun 8, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.